News & Events:MRK

Data from studies of six medicines and pipeline candidates in more than 25 cancers to be presented Merck (MRK), known as MSD outside the United States and Canada, today announced that data for six approved medicines and pipeline candidates in more than 25 types of cancer will be presented at the 2022 American Society of Clinical Oncology Annual Meeting in Chicago from June 3-7.

On CNBC's "Halftime Report Final Trades," Stephen Weiss of Short Hills Capital Partners chose Invesco QQQ Trust Series 1. "The market will rally off the Fed," Weiss said. For those intending to ride the rally, he recommended to "use a tight stop on it, so you don't get run over." Liz Young of BNY Mellon Investment Management chose the Vanguard Short-Term Treasury Index Fund ETF.

JERSEY CITY, N.J.---- Organon, today announced its results for the first quarter ended March 31, 2022. "The first quarter marked a solid start to the year. Total net revenue was $1,567 million for the first quarter of 2022, an increase of 4% as-reported and an increase of 8% excluding the impacts of foreign currency, compared with the first quarter of 2021.

CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Broadcom Inc 12:30 P.M. - Stephanie Link mentioned she sold Broadcom, shares slid 0.07% lower in the following 30 minutes.

Merck (MRK), known as MSD outside the United States and Canada, today announced that Executive Vice President and Chief Financial Officer Caroline Litchfield will participate in a fireside chat at the live Bank of America Securities 2022 Healthcare Conference. The conversation will take place Wednesday, May 11, at 11:40 a.m. ET.

Imugene Ltd (IUGNF): * ANNOUNCED TERMINATION OF ITS SUPPLY AGREEMENT WITH MSD Source text for Eikon: Further company coverage:

Markets finished off the month of April down big amid a mixed first-quarter earnings season. For the month, the Nasdaq fell 15%, the S&P 500 fell 10.2% and the Dow fell 6.4%. On Thursday, the Commerce Department reported first-quarter U.S. GDP fell 1.4%, well short of economists' expectations of 1% growth.

Over the past 3 months, 7 analysts have published their opinion on Merck & Co stock. These 7 analysts have an average price target of $97.43 versus the current price of Merck & Co at $88.61, implying upside. Below is a summary of how these 7 analysts rated Merck & Co over the past 3 months.

Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA has approved Bristol Myers Squibb & Co's  Camzyos for obstructive hypertrophic cardiomyopathy to improve functional capacity and symptoms. Camzyos is the first and only FDA-approved allosteric and reversible inhibitor selective for cardiac myosin that targets the underlying pathophysiology of obstructive HCM.

Merck & Co Inc (MRK): * BIOCYTOGEN PHARMACEUTICALS CO., LTD. - ENTERED INTO EVALUATION AND OPTION AGREEMENT WITH MERCK Source text for Eikon: Further company coverage:

Merck & Co Inc (MRK): * EUROPEAN COMMISSION APPROVES MERCK'S KEYTRUDA® FOR PATIENTS WITH MICROSATELLITE INSTABILITY-HIGH OR DEFICIENT MISMATCH REPAIR TUMORS IN FIVE DIFFERENT TYPES OF CANCER. * MERCK (MRK) - APPROVAL ALLOWS MARKETING OF KEYTRUDA MONOTHERAPY IN ALL EUROPEAN UNION MEMBER STATES PLUS ICELAND, LICHTENSTEIN, NORWAY AND NORTHERN IRELAND Source text for Eikon: Further company coverage:

KEYTRUDA is the First Immunotherapy to be Approved for Patients with MSI-H/dMMR Biomarkers in Five Different Types of Cancer in Europe Merck (MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, as monotherapy for the treatment of microsatellite instability-high or deficient mismatch repair tumors in ...

First Immunotherapy-Based Regimen Approved in Europe for These Patients With Persistent, Recurrent or Metastatic Cervical Cancer Approval Based on Overall Survival Benefit Demonstrated in Phase 3 KEYNOTE-826 Trial Merck (MRK), known as MSD outside the United States and Canada, today announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemothe...

U.S. indices traded higher Thursday despite a drop in U.S. GDP. U.S. GDP unexpectedly declined 1.4% in the first quarter, falling well short of consensus economist estimates of 1% growth... Here are the day's winners and losers from the Dow Jones, according to data from Benzinga Pro. Salesforce Inc, Merck & Co., Inc. and Nike Inc were among the top gainers for the DIA.

- The following is a summary of some recent studies on COVID-19. Pandemic linked with mental health issues in kids. The COVID-19 pandemic has profoundly impacted the mental health of children and adolescents, researchers say, based on their analysis of findings from 17 earlier studies.

The following is a summary of some recent studies on COVID-19. Pandemic linked with mental health issues in kids. The COVID-19 pandemic has profoundly impacted the mental health of children and adolescents, researchers say, based on their analysis of findings from 17 earlier studies.

This post contains sponsored advertising content. The bulls approached another run as the major indexes try to stay above key support levels.

Despite a global boycott of Russia and an international condemnation of the Kremlin's actions against Ukraine, some multinationals have dismissed demands to exit or scale down their presence in Russia for various reasons and choosing to continue business-as-usual. The conflict between Russia and Ukraine has dragged on for two months now since Russia started invading Ukraine on Feb. 24.

Here's a roundup of top developments in the biotech space over the last 24 hours: Moderna Inc  submitted a request for FDA emergency use authorization  for its COVID-19 vaccine in children 6 months to under 6 years of age. The requests are based on a 25 μg two-dose primary series of mRNA-1273. The EUA submission for children ages 6 months to under 6 years will be complete next week.

Merck Clocks 50% Q1 Sales Growth Boosted By COVID-19 Treatment, Tightens FY22 EPS Outlook